Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines

Affiliations

¹ Division of Infection and Immunity, University College London, London, UK; Department of Medical Microbiology, University College London Hospitals NHS Trust, London, UK.
² Henry M Jackson Foundation-Division of AIDS, TB Clinical Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
³ Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; CAST, Karolinska University Hospital, Stockholm SE-14186, Sweden. Electronic address: markus.maeurer@ki.se.

Alimuddin I Zumla et al. Lancet Infect Dis. 2014 Apr.

. 2014 Apr;14(4):267-9.

doi: 10.1016/S1473-3099(14)70028-3.

¹ Division of Infection and Immunity, University College London, London, UK; Department of Medical Microbiology, University College London Hospitals NHS Trust, London, UK.
² Henry M Jackson Foundation-Division of AIDS, TB Clinical Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
³ Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; CAST, Karolinska University Hospital, Stockholm SE-14186, Sweden. Electronic address: markus.maeurer@ki.se.

No abstract available

MeSH terms